Biogen (NASDAQ 🙂 reported Tuesday that the first quarter revenue exceeded expectations and that it missed analyst forecasts.

Biogen posted earnings per share (EPS) of $3.62 on revenues of $2.53 billion. Investing.com polled analysts and predicted EPS at $4.34 for revenue of $2.5B.

Biogen shares have risen 6.49% since the start of the year. However, they are still 55.72% below their 52-week high of $468.20 on June 7, 2021. They outperform the, which has fallen 19.88% since the beginning of the year.

Biogen’s earnings are in line with other top Healthcare sectors this month

Biogen’s announcement follows an earnings beat of UnitedHealth on April 14. UnitedHealth reported EPS in the range of $5.49 to $80.15B on revenue, while Biogen forecasts EPS in the range of $5.36 to $78.73B.

J&J had beat expectations on April 19 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.

You can keep up to date on the latest earnings reports at www.investors.com Investing.com’s earnings calendar